8-K: Moleculin Biotech Reports Positive AML Trial Data

Moleculin Biotech announces updated preliminary blinded results from its Phase 2/3 MIRACLE trial for Annamycin in R/R AML, showing promising remission rates, especially in patients who failed prior venetoclax therapy.

Summary

• Moleculin Biotech has released updated preliminary blinded results from Part A of its Phase 2/3 MIRACLE trial for Annamycin in combination with cytarabine (AnnAraC) for relapsed or refractory acute myeloid leukemia (R/R AML).
• The trial has evaluated 62 subjects to date, showing a preliminary blinded complete remission (CR) rate of 24% and a composite complete remission (CRc) rate of 37%.
• Notably, among the 30 subjects (48% of the evaluable population) who had previously failed a venetoclax-based regimen, the CR rate was 23% and the CRc rate was 37%, which is approximately three times the published salvage remission rates of 13% for this patient subgroup.
• Enrollment has reached 74 out of 90 patients, with the final patient expected to be treated in September 2026.
• Comprehensive unblinded Part A results are on track for the December 2026-February 2027 timeframe.
• The trial continues to show no evidence of cardiotoxicity, a key differentiator for Annamycin compared to conventional anthracyclines.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to strong preliminary efficacy data, especially in a difficult-to-treat patient subgroup, and the absence of cardiotoxicity. However, the need for future financing and the preliminary nature of the data temper the score.

Positives

• Preliminary blinded CRc rate of 37% in R/R AML patients, which is significantly higher than the published 13% salvage remission rate for patients who have failed prior venetoclax therapy.
• The efficacy in patients who failed prior venetoclax therapy (CRc of 37%) is identical to the overall evaluable population, suggesting prior treatment failure does not diminish Annamycin's effectiveness.
• No evidence of cardiotoxicity observed, differentiating Annamycin from conventional anthracyclines.
• Enrollment is progressing well, with 74 of 90 patients enrolled, and the final patient expected to be treated in September 2026.
• The blinded CRc rate has remained stable within a narrow band (37%-40%) across successive analyses, despite an increasing proportion of heavily pre-treated patients entering the trial.
• Annamycin has Fast Track Status and Orphan Drug Designation from the FDA for R/R AML, and Orphan Drug Designation from the EMA for R/R AML.

Negatives

• The reported CR and CRc rates are preliminary and blinded, and are expected to be lower than the unblinded Annamycin-arm results.
• The trial is not powered for subgroup comparisons, meaning the results in the venetoclax-failure subgroup are descriptive only.
• Moleculin Biotech will require significant additional financing to conduct its clinical trials, and there are no current commitments for this financing.

Risks

• The preliminary blinded data may differ from the final locked efficacy and safety results.
• The company requires significant additional financing, with no current commitments, to continue its clinical trials.
• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially.
• The trial is not powered for subgroup comparisons, limiting the statistical significance of findings within specific patient groups.

Future Outlook

Comprehensive unblinded Part A results are anticipated between December 2026 and February 2027, which could validate Annamycin's profile, support advancement to Part B, strengthen the regulatory pathway, and expand strategic partnering opportunities. The company expects to treat the 90th subject in September 2026.

Management Comments

• Nearly half of our evaluable subjects have now entered the trial having failed prior venetoclax therapy, a group for which published salvage remission rates are approximately 13% and median survival approximately 2.4 months. Within that subgroup, our blinded CRc is also approximately 37%, indistinguishable from the evaluable population as a whole, which suggests prior venetoclax failure is not diminishing the remissions we are seeing.
• Because this analysis is still blinded and includes control-arm subjects, we would expect it to sit below the unblinded Annamycin-arm results we reported in June. That it has held in a narrow band while the population became measurably harder to treat is what gives us added confidence as we approach the completion of Part A.
• Just as importantly, based on reported ejection fractions and adverse events, we continue to observe no evidence of cardiotoxicity, one of the defining characteristics that differentiates Annamycin from conventional anthracyclines.
• We believe the combination of encouraging efficacy, continued cardiac safety, and rapid enrollment progress positions MIRACLE for what could be its most important period yet.
• We believe these upcoming milestones could represent transformational events for Moleculin and our shareholders.

Industry Context

StockSavvy.ai notes that the positive interim data for Annamycin in R/R AML, particularly in the challenging venetoclax-refractory patient population, is a significant development. The drug's potential to avoid cardiotoxicity, a major limitation of existing anthracyclines, could position it as a valuable therapeutic option in a market with high unmet needs.

Comparison to Industry Standards

• Published salvage remission rates following first-line venetoclax failure are approximately 13%, whereas the current blinded CRc rate in the venetoclax-failure subgroup of the MIRACLE trial is 37%.
• Median survival for patients with R/R AML following venetoclax failure is approximately 2.4 months, compared to the potential for improved survival with Annamycin.
• The MIRACLE trial's Part A interim analysis (n=45) showed CR rates of 43% and 36% for Annamycin arms versus 12% for control, and CRc rates of 50% and 57% versus 29% for control, all after a single cycle of therapy.
• Historical benchmarks like the MIRROS and CLASSIC I studies, and Moleculin's own MB-106 study, permitted multiple cycles of treatment, which typically yield higher absolute remission rates than the single-cycle approach in MIRACLE Part A.

Stakeholder Impact

• Shareholders: Potential for increased valuation if Annamycin gains regulatory approval and commercial success, but also risk associated with the need for significant future financing.
• Patients: Potential for a new, effective, and safer treatment option for R/R AML, particularly for those who have failed prior venetoclax therapy.
• Healthcare Providers: Opportunity to utilize a differentiated therapy with a favorable safety profile (lack of cardiotoxicity) in AML treatment.

Next Steps

• Complete enrollment of 90 patients in Part A of the MIRACLE trial by September 2026.
• Unblind comprehensive Part A data between December 2026 and February 2027.
• Support advancement into Part B of the trial.
• Strengthen regulatory pathway for Annamycin.
• Expand strategic partnering opportunities.
• Secure significant additional financing for ongoing clinical trials.

Key Dates

Recommendation

The preliminary data is encouraging, particularly the efficacy in the venetoclax-refractory group and the lack of cardiotoxicity. However, the company's reliance on future, uncommitted financing and the preliminary nature of the blinded data warrant a 'hold' recommendation until more definitive unblinded results and financing clarity emerge.

Keywords

Annamycin, Acute Myeloid Leukemia, Relapsed Refractory AML, Clinical Trial, Oncology, Pharmaceutical, Venetoclax Failure, Cardiotoxicity